A study analysing the health records of people with COVID-19 has found that those who were taking SSRI antidepressants were less likely to die from the virus.
There was an 8% reduction for any SSRI, 28% for fluoxetine, & 26% for fluoxetine or fluvoxamine. jamanetwork.com/journals/jaman…
The researchers tried to match people taking antidepressants with a group of control patients, based on age, sex, ethnicity, and medical history.
However, this wasn’t a randomised controlled trial, and it’s possible that other unmeasured factors affected the results.
That said, it’s plausible that SSRI antidepressants do reduce the risk of dying from COVID-19, because they have both anti-viral and anti-inflammatory properties. jamanetwork.com/journals/jaman…
If the results of this study are replicated in randomised controlled trials, a short course of these medications could perhaps be offered to people with COVID-19. Because generic versions are available at low cost, this could save many lives in developing countries in particular.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
The AY.33 sub-lineage of the delta variant might not be readily detectable with current PCR or rapid antigen tests. These can be updated, but in the interim, cases may go undetected.
This is one reason why Australia’s plan to end hotel or home quarantine is premature.
This isn’t the first time variants have caused testing issues. One of the reasons the alpha variant was noticed was because tests for the spike gene returned false negatives.
Fortunately, the tests also looked for other parts of the virus, which had not changed significantly.
A variant also emerged in France that was difficult to detect. Viral loads in the upper (but not lower) respiratory tract were often below the detectable limit in people infected with the B.1.616 variant. medrxiv.org/content/10.110…
Long COVID is real, and we need to protect children from it. In Israel, long COVID clinics for children are busy. The clinic at the Schneider Children’s Medical Center in Petah Tikva has about 150 patients and hundreds more are waiting for treatment. 🧵 haaretz.com/israel-news/th…
Liat Ashkenazi-Hoffnung, a clinic doctor says that in some children long COVID "appears as a direct continuation of severe illness but in very many of the children, there is a severe illness, followed by a lull of several months and only then do the symptoms of long COVID begin."
Many children fully recover, but it can take time.
Ashkenazi-Hoffnung says "we had a boy here who was a competitive swimmer and came down with long COVID and was very anxious and in pain. After half a year he went back to swimming and even broke a personal record."
A new study of weekly testing of children and staff at a Belgian primary school shows what we’ve always suspected: if mitigation measures aren’t in place, transmission is common between children and adults at school, and it spills over into households. jamanetwork.com/journals/jaman…
Although there are issues with waning immunity, current COVID-19 vaccines offer excellent protection. But this might not always be the case. Future variant-specific boosters may preferentially boost responses to the original strain and be less effective.🧵 cell.com/trends/immunol…
The theory works like this: a person exposed to strain A of the virus (either by vaccination or infection) may prime their immune system such that the ability to make future antibodies specific to a future strain (strain B) is reduced.
This is known as immune imprinting.
In that scenario, a vaccine booster for strain B will give some protection against the new strain B, but the immune system will preferentially produce antibodies against the original strain A.
Study of people with mild or moderate (but not hospitalised) COVID-19 from the first wave in Geneva. 7-9 months later, at least 25% had >=1 persisting symptom. Most common: fatigue (14%); loss of smell/taste (11%); headache (7%); shortness of breath (8%). acpjournals.org/doi/10.7326/M2…
Note: These proportions were calculated using the entire study sample as the denominator. However, one-third of people were lost to follow-up and their health status was unknown. It’s therefore possible that the proportion of people experiencing persistent symptoms was higher.
Of those with fatigue, 27% said they were limited in strenuous activity. 60% of those with shortness of breath experienced this when walking up a slight hill or when hurrying. Most people with headache or loss of smell or taste reported at least moderate symptoms.